Roche plans $50B investment in US over 5 years for R&D and manufacturing, including 4 new facilities and expansions, amid ...

AstraZeneca/Daiichi's Enhertu plus Perjeta shows better progression-free survival vs standard care in first-line HER2+ ...

Alvogen plans to fight a court decision that could significantly delay its ability to bring a generic version of Bausch ...

Gilead's antibody-drug conjugate Trodelvy combined with Merck's Keytruda reduced the risk of disease progression or death in ...

Chinese biotech HuidaGene reports early success with first CRISPR brain treatment in 9-year-old with MECP2 duplication ...

Roivant is changing its strategy for Immunovant roughly a month after its subsidiary decided it wouldn’t take one of its ...

The FDA made two de­ci­sions on Re­gen­eron’s best-sell­ing drugs Fri­day, hand­ing down one ap­proval and one re­jec­tion.

CDMOs fear that FDA site inspections might slow down due to the mass staffing cuts at the federal health agencies.

Sanofi is teaming up with a private biotech in Delaware on a pair of bispecific antibodies for autoimmune and inflammatory ...

A hot antibody discovery team in China has signed its second US biotech deal in less than six months, marking the latest sign ...

Verve Therapeutics is trying to swerve the gene editing industry downturn with new results on a potential one-time treatment ...

Under the 11-page 'roadmap' outlined Thursday, the goal is for animal testing to become 'the exception rather than the norm' ...